Iron supplementation in chronic kidney SEO Brief & AI Prompts

Iron therapy in chronic kidney disease is administered orally or intravenously depending on iron indices and clinical setting; KDIGO recommends considering IV iron in hemodialysis patients with transferrin saturation (TSAT) ≤30% and ferritin ≤500 ng/mL. Oral iron (ferrous salts or ferric maltol) remains appropriate for many nondialysis CKD patients with mild iron deficiency—classically TSAT <20% and ferritin <100 ng/mL—if absorption and adherence are expected. Intravenous iron is preferred when oral absorption is limited by elevated hepcidin, when erythropoiesis‑stimulating agents (ESAs) are used, or when dialysis access allows safe infusion. Choice should be guided by lab monitoring of ferritin and TSAT.

Reduced intestinal absorption of oral iron in CKD is mediated by hepcidin-driven ferroportin internalization and systemic inflammation, which lowers fractional absorption to roughly 10–20% in iron‑replete states. Ferritin and transferrin saturation (ferritin/TSAT) are the standard tools for assessing iron stores and guide therapy per KDIGO recommendations. Oral iron CKD regimens (e.g., ferrous sulfate 65 mg elemental iron two to three times daily or newer ferric maltol formulations) can correct deficiency when absorption is intact, while intravenous iron CKD options—iron sucrose, ferric carboxymaltose, ferric derisomaltose—bypass absorption barriers and rapidly replenish stores. ESAs increase iron utilization, necessitating IV dosing strategies and closer ferritin/TSAT surveillance. The Ganzoni formula estimates total iron deficit for individualized dosing, and PIVOTAL informed dosing safety for dialysis cohorts.

A central nuance is that oral iron CKD and intravenous iron CKD are not pharmacologically interchangeable because of bioavailability, hepcidin-mediated blockade, and differing kinetics of iron redistribution. For example, in iron deficiency anemia CKD a nondialysis patient with TSAT 18% and ferritin 80 ng/mL may be a candidate for an oral trial if absorption and adherence are probable, whereas a hemodialysis patient with the same labs who is receiving an ESA will commonly be managed with IV iron to achieve timely iron repletion. Iron dosing CKD decisions also differ for urgent needs (rapid repletion with IV formulations) versus maintenance (staged oral or intermittent IV dosing). Allergic reactions are uncommon with current formulations; monitor during infusion and for infection.

Clinicians should base iron therapy in CKD on measured ferritin and TSAT, choose an oral trial for nondialysis patients with mild iron deficiency and intact absorption, and favor intravenous iron for hemodialysis, ESA‑treated patients, intolerance to oral agents, or when rapid repletion is required. Typical practice is to reassess ferritin and TSAT one month after IV administration and every 1–3 months during active repletion or ESA therapy, adjusting iron dosing CKD strategies to avoid sustained ferritin elevation. Documentation of formulation, total dose, and post‑treatment labs supports safety surveillance. Clinicians should document rationale clearly. This page contains a structured, step‑by‑step framework.